ChemicalBook > CAS DataBase List > Azintuxizumab
Azintuxizumab
- Product Name
- Azintuxizumab
- CAS No.
- 1826819-57-1
- Chemical Name
- Azintuxizumab
- Synonyms
- Azintuxizumab;Research Grade Azintuxizumab;Research Grade Azintuxizumab (DHJ64002)
- CBNumber
- CB58081026
- Formula Weight
- 0
- MOL File
- Mol file
More
Less
Azintuxizumab Property
- form
- Liquid
- color
- Colorless to light yellow
More
Less
Azintuxizumab Chemical Properties,Usage,Production
Uses
Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin[1].
References
[1] International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 31, No. 3, 2017.
Azintuxizumab Preparation Products And Raw materials
Raw materials
Preparation Products
More
Less
Azintuxizumab Suppliers
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8000
- Advantage
- 62
- Tel
- 027-65317797 15926423062
- Fax
- QQ:422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9868
- Advantage
- 58
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 6762
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11973
- Advantage
- 58
- Tel
- 0731-13823398 15111215862
- 313359644@qq.com
- Country
- China
- ProdList
- 4161
- Advantage
- 58
- Tel
- 17316404525 17316404525
- 209533805@qq.com
- Country
- China
- ProdList
- 9763
- Advantage
- 58
- Tel
- 027-87008169 17762441161
- info@atagenix.com
- Country
- China
- ProdList
- 10001
- Advantage
- 58
- Tel
- 33175446423
- support@antibodysystem.com
- Country
- China
- ProdList
- 6739
- Advantage
- 58
- Tel
- 51288865780
- sales@biosynth.com
- Country
- China
- ProdList
- 6051
- Advantage
- 58
1826819-57-1, AzintuxizumabRelated Search:
Quilizumab
Zuberitamab
Bermekimab
Sibrotuzumab
Research Grade Acazicolcept (DHC83404)
Teclistamab
Miromavimab
Socazolimab
reslizumab
Ubamatamab